ADVERTISEMENT

Piramal Pharma Q2 Results Review - Healthy Recovery In Operational Performance: Motilal Oswal

Higher interest costs hurt earnings.

<div class="paragraphs"><p>Piramal Pharma Ltd.'s formulation manufacturing unit. (Source: Company website)</p></div>
Piramal Pharma Ltd.'s formulation manufacturing unit. (Source: Company website)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit